Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and …
Patients with multiple myeloma (MM) are at an elevated risk of venous thromboembolism
(VTE), which is further increased for those undergoing anti‐myeloma therapy. Current …
(VTE), which is further increased for those undergoing anti‐myeloma therapy. Current …
Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma
Simple Summary There is a significant risk of thrombotic complications in patients with
multiple myeloma. Patient-related, disease-related, and treatment-related risk factors …
multiple myeloma. Patient-related, disease-related, and treatment-related risk factors …
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc …
The introduction of new therapeutic agents for multiple myeloma (MM), including
proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved …
proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved …
Cerebrovascular manifestations in hematological diseases: an update
JM Ferro, J Infante - Journal of Neurology, 2021 - Springer
Patients with hematological diseases often experience cerebrovascular complications
including ischemic stroke, intracerebral and subarachnoid hemorrhage, microbleeds …
including ischemic stroke, intracerebral and subarachnoid hemorrhage, microbleeds …
Thrombosis in multiple myeloma: mechanisms, risk assessment and management
O Jarchowsky, O Avnery, MH Ellis - Leukemia & Lymphoma, 2023 - Taylor & Francis
Multiple myeloma (MM) is associated with an increased risk of venous and arterial
thrombosis. Pathophysiologic mechanisms include patient, disease and treatment related …
thrombosis. Pathophysiologic mechanisms include patient, disease and treatment related …
Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival
C Charalampous, U Goel, P Kapoor… - American journal of …, 2023 - Wiley Online Library
Lenalidomide‐containing (R) triplet and quadruplet regimens are the standard of care for
multiple myeloma (MM) and have been shown to increase the risk of thrombosis. The …
multiple myeloma (MM) and have been shown to increase the risk of thrombosis. The …
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Patients with multiple myeloma are at increased risk of vascular thromboembolic events
(VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study …
(VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study …
Advances in the management of cancer-associated thrombosis
The association between cancer and venous thromboembolism (VTE) has been established
for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major …
for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major …
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple …
X Li, X Sun, B Fang, Y Leng, F Sun, Y Wang, Q Wang… - Thrombosis …, 2023 - Springer
Background Individuals with multiple myeloma (MM) receiving immunomodulatory drugs
(IMiDs) are at risk of develo** venous thromboembolism (VTE), a serious complication …
(IMiDs) are at risk of develo** venous thromboembolism (VTE), a serious complication …
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma
Multiple myeloma management requires a balance between maximizing survival,
minimizing adverse events to therapy, and monitoring disease progression. While previous …
minimizing adverse events to therapy, and monitoring disease progression. While previous …